Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy

Oncology

Volumn 81, Issue 1, 2011, Pages 30-38

  Keskin, Serkan ^a,b   Muslumanoglu, Mahmut ^b   Saip, Pinar ^a   Karanlik, Hasan ^a   Guveli, Murat ^a   Pehlivan, Esmehan ^b   Aydoǧan, Fatma ^a   Eralp, Yesim ^a   Aydiner, Adnan ^a   Yavuz, Ekrem ^b   Ozmen, Vahit ^b   Igci, Abdullah ^b   Topuz, Erkan ^a  

^a Institute of Oncology   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Anthracycline; Clinicopathologicparameters; Neoadjuvantchemotherapy; Pathologicalcomplete response; Survival

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; LETROZOLE; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLA; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LOADING DRUG DOSE; LYMPH NODE; MAJOR CLINICAL STUDY; MENOPAUSE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROSPECTIVE STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052556516     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000330766     Document Type: Article

References (38)

1. Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, Cancello G, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Zurrida S, Gentilini O, Mastropasqua MG, Bottiglieri L, Iorfida M, Goldhirsch A, Colleoni M: Pathological complete response after preoperative systemic therapy and outcome: Relevance of clinical and biologic baseline features. Breast Cancer Res Treat 2010; 124: 689-699.
2. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez- Angulo AM: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-1044. (Pubitemid 46638799)
3. Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ: Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002; 80: 4-11. (Pubitemid 34477727)
4. Ionta MT, Atzori F, Deidda MC, Pusceddu V, Palmeri S, Frau B, Murgia M, Barca M, Minerba L, Massidda B: Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response ( ! pCR) after primary chemotherapy. Oncologist 2009; 14: 1051-1060.
5. Penault-Llorca F, Abrial C, Raoelfils I, Chollet P, Cayre A, Mouret-Reynier MA, Thivat E, Mishellany F, Gimbergues P, Durando X: Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2008; 13: 1235-1245.
6. Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhaberle E, Holtrich U, von Minckwitz G, Kaufmann M: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GeparTrio trial: HER-2, but not topoisomerase II alpha and microtubuleassociated protein tau, is highly predictive of tumor response. Breast 2007; 16: 86-93. (Pubitemid 46172862)
7. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson GD: Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005; 92: 147-155. (Pubitemid 40188448)
8. Alvarado-Cabrero I, Alderete-Vazquez G, Quintal-Ramirez M, Patino M, Ruiz E: Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: Correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings. Ann Diagn Pathol 2009; 13: 151-157.
9. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
10. Makris A, Powles TJ, Dowsett M, Allred C: P53 protein overexpression and chemosensitivity in breast cancer. Lancet 1995; 345: 1181-1182.
11. Alkarain A, Slingerland J: Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. Breast Cancer Res 2004; 6: 13-21. (Pubitemid 38195556)
12. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791. (Pubitemid 39095313)
13. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994; 12: 454-466. (Pubitemid 24079885)
14. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL: Staging system for breast cancer: Revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003; 83: 803-819. (Pubitemid 36841911)
15. The World Health Organization Histological Typing of Breast Tumors - Second Edition. The World Organization. Am J Clin Pathol 1982; 78: 806-816.
16. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I, Elston C: Histological grading of breast carcinomas: A study of interobserver agreement. Hum Pathol 1995; 26: 873-879.
17. Osako T, Horii R, Matsuura M, Ogiya A, Domoto K, Miyagi Y, Takahashi S, Ito Y, Iwase T, Akiyama F: Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy. J Cancer Res Clin Oncol 2010; 136: 233-241.
18. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr., Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685. (Pubitemid 28363030)
19. Charfare H, Limongelli S, Purushotham AD: Neoadjuvant chemotherapy in breast cancer. Br J Surg 2005; 92: 14-23. (Pubitemid 40144188)
20. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82: 1539-1545. (Pubitemid 20296503)
21. Sarid D, Ron IG, Sperber F, Stadler Y, Kahan P, Kovner F, Ben-Yosef R, Marmor S, Grinberg Y, Maimon N, Weinstein J, Yaal- Hahoshen N: Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: A phase II study. Clin Drug Investig 2006; 26: 691-701. (Pubitemid 44901698)
22. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN: Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 2005; 23: 7098-7104.
23. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Hogel B, Darb-Esfahani S, Mehta K, Loibl S: Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: Overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124: 133-140.
24. Cocquyt VF, Blondeel PN, Depypere HT, Praet MM, Schelfhout VR, Silva OE, Hurley J, Serreyn RF, Daems KK, Van Belle SJ: Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 2003; 29: 361-367. (Pubitemid 36675693)
25. Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altorjai G, Zielinski CC, Lang A, Haid A, Jakesz R, Gnant M, Steger GG: Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res Treat 2007; 104: 109-114. (Pubitemid 46976638)
26. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, Contesso G, Delaloge S, Spielmann M: The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004; 40: 342-351. (Pubitemid 38121270)
27. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretiere JM, Bouita L, Cohen-Solal C, Cherel P, Rouesse J: Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: A retrospective study on 860 patients from one institution. Ann Oncol 2006; 17: 1228-1233. (Pubitemid 44288213)
28. von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 2008; 10:R30.
29. Prisack HB, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, Bojar H: Predictive biological markers for response of invasive breast cancer to anthracycline/ cyclophosphamide-based primary (radio-) chemotherapy. Anticancer Res 2005; 25: 4615-4621. (Pubitemid 41729522)
30. Fernández-Morales LA, Segui MA, Andreu X, Dalmau E, Saez A, Pericay C, Santos C, Montesinos J, Gallardo E, Arcusa A, Saigi E: Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status. Clin Breast Cancer 2007; 7: 559-564. (Pubitemid 46725249)
31. Pu RT, Schott AF, Sturtz DE, Griffith KA, Kleer CG: Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: Importance of tumor necrosis. Am J Surg Pathol 2005; 29: 354-358. (Pubitemid 40321971)
32. Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA: Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg 2009; 198: 520-525.
33. Zhu L, Li YF, Chen WG, He JR, Peng CH, Zhu ZG, Li HW: HER2 and topoisomerase IIα : Possible predictors of response to neoadjuvant chemotherapy for breast cancer patients. Chin Med J (Engl) 2008; 121: 1965-1968.
34. Shien T, Akashi-Tanaka S, Miyakawa K, Hojo T, Shimizu C, Seki K, Ando M, Kohno T, Taira N, Doihara H, Katsumata N, Fujiwara Y, Kinoshita T: Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. World J Surg 2009; 33: 44-51.
35. Uematsu T, Kasami M, Watanabe J, Takahashi K, Yamasaki S, Tanaka K, Tadokoro Y, Ogiya A: Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer? Breast Cancer 2010, E-pub ahead of print.
36. Tamura N, Hasebe T, Okada N, Houjoh T, Akashi-Tanaka S, Shimizu C, Shibata T, Sasajima Y, Iwasaki M, Kinoshita T: Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy. Cancer Sci 2009; 100: 1823-1833.
37. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M: Neoadjuvant vinorelbine- capecitabine versus docetaxel-doxorubicin- cyclophosphamide in early nonresponsive breast cancer: Phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100: 542-551.
38. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785. (Pubitemid 351264391)